Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04086459
Other study ID # Addiction-No.1
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date June 1, 2019
Est. completion date July 1, 2022

Study information

Verified date January 2021
Source Tang-Du Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Heroin addiction is a serious problem and the relapse rate of existing treatment methods is extremely high. Recently, international journals such as Science reported that repetitive transcranial magnetic stimulation (rTMS) can reduce the craving of addicts, alleviate depression and anxiety symptoms, and is expected to become an effective treatment. Our preliminary experiment using rTMS to stimulate the left dorsolateral prefrontal cortex of heroin addicts also showed similar effects, however, the mechanism is unclear. Previously, the investigators found that the functional connectivity between left executive control network and default mode network was negatively correlated relapse behavior, while the functional connectivity between salience network and default mode network was positively correlated with relapse behavior. Studies have shown that dopamine dysfunction in addicts and brain metabolism is the biological basis of network connectivity. It suggests that elucidating the relationship between the characteristics of large brain network connectivity and the level of dopamine receptor and relapse behavior in addicts is hopeful to further understand the neurological mechanism of rTMS treatment for addiction. In this project, the investigators intend to observe the changes of brain network connectivity, glucose metabolism and dopamine D2 receptor before and after rTMS treatment in addicts from the perspective of large brain network by combining PET/MRI with psychobehavioral approach. The relationship between rTMS and relapse behavior will be deeply analyzed to provide scientific basis for the development of effective treatment programs.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 90
Est. completion date July 1, 2022
Est. primary completion date July 1, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 55 Years
Eligibility Inclusion Criteria for Heroin-dependent Participants: - Clinical diagnosis of heroin addiction - Have been receiving treatment in a methadone maintenance treatment program for no less than 6 months - have been on a stable dose for at least 1 month before entering the study - Right-handed Inclusion Criteria for Healthy Control Participants: - Clinical diagnosis of Healthy Control - Right-handed Exclusion Criteria for all Participants: - Current or past psychiatric illness other than heroin and nicotine dependence - Neurological signs and/or history of neurological disease - History of head trauma - History of cardiovascular or endocrine disease - Current medical illness or recent medicine use - Presence of magnetically active objects in the body - Claustrophobia or any other medical condition that would preclude the participant from lying in the PET/MRI scanner for approximately 40 min.

Study Design


Intervention

Device:
Repetitive transcranial magnetic stimulation
Those receiving experimental treatment will receive 20 sessions of rTMS, stimulation protocol included 20 sessions within 30 days (once a day, 5 days/week, 4 weeks, 10 Hz frequency, pulse intensity 100% of the resting motor threshold, 50 pulses per train, inter train pause of 10 s, 40 stimulation trains, 2000 pulses/ session)

Locations

Country Name City State
China Tangdu Hospital Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Tang-Du Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of craving Craving scores will be assessed with visual analogue scale Baseline, 1 week later, 1,2,3,4,5,6 months later
Primary Change of protracted-abstinence symptoms Protracted-abstinence symptoms scores will be assessed with protracted symptoms questionnaire Baseline, 1 week later, 1,2,3,4,5,6 months later
Primary Change of depress symptoms Depress symptoms scores will be assessed with Beck Depression Inventory Baseline, 1 week later, 1,2,3,4,5,6 months later
Primary Change of anxiety symptoms Anxiety symptoms scores will be assessed with Hamilton Anxiety Scale Baseline, 1 week later, 1,2,3,4,5,6 months later
Primary Change of impulsive behaviors Impulsive behaviors scores will be assessed with Barratt impulsiveness scale Baseline, 1 week later, 1,2,3,4,5,6 months later
Primary Change of sleep Sleep scores will be assessed with Pittsburgh sleep quality index Baseline, 1 week later, 1,2,3,4,5,6 months later
Primary Change of functional connectivity between dorsolateral prefrontal cortex and whole brain Functional connectivity based on dorsolateral prefrontal cortex will be measured with magnetic resonance imaging based on blood oxygen level dependence Baseline, 1 week later, 1,3,6 months later
Primary Change of gray matter volume of whole brain Gray matter volume will be measured with magnetic resonance imaging (high resolution T1-weighted image) Baseline, 1 week later, 1,3,6 months later
Primary Change of white matter integrity of whole brain Fractional anisotropy, axial diffusivity and radial diffusivity will be measured with magnetic resonance imaging (diffusion tensor imaging) Baseline, 1 week later, 1,3,6 months later
Primary Change of availability of dopamine 2 receptor of whole brain Accumulation of 11C-raclopride will be analyzed by time-related Positron emission tomography Baseline, 1 month later
Primary Change of metabolism of glucose in the brain Accumulation of 18F-FDG will be analyzed by time-related Positron emission tomography Baseline, 1 month later
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT00306813 - Evaluation of Lenalidomide, Doxorubicin and Dexamethasone (RAD) in Patients With Relapsed or Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT01956695 - Efficacy of Lenalidomide With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma Phase 2
Not yet recruiting NCT05926167 - Observational Trial Evaluating Elevated Factor VIII Related Labs as a Biomarker for Incomplete Relapse Recovery
Recruiting NCT03710512 - Evaluation of Early Relapse After Mandibular Lengthening Surgery
Recruiting NCT04921540 - Ingrown Toenails : Surgery Only Versus Surgery + Chemical Cauterization With TCA N/A
Not yet recruiting NCT03830827 - MBRP + Vortioxetine VS MBRP on Preventing Relapse in Chronic MA Users Phase 4
Completed NCT05250765 - Comparison of Efficiency and Effectiveness of Two Types of Bonded Orthodontic Retainers: an RCT. N/A
Completed NCT05915273 - Relapse and Failure Rates Between CAD/CAM and Conventional Fixed Retainers N/A
Active, not recruiting NCT04389879 - CAD/CAM Fixed Retainers vs. Conventional Multistranded Fixed Retainers in Orthodontic Patients. Comparison of Stability, Retainer Failure Rate, Adverse Effects, Cost-effectiveness, and Patient Satisfaction. A Randomized Controlled Clinical Trial N/A
Completed NCT02145403 - Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies Phase 1/Phase 2
Completed NCT01481701 - A Trial Evaluating Efficacy and Safety of Oxaliplatin With 5-Fluorouracil in Patients With Recurrent Ovarian Carcinoma Phase 2
Recruiting NCT01941394 - Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation Phase 2
Recruiting NCT04723901 - Dual Target CAR-T Cells in B-cell Acute Lymphoblastic Leukemia Phase 1/Phase 2
Not yet recruiting NCT04994626 - Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies Phase 2
Recruiting NCT06292364 - Comparison of Retention Characteristics of Immediate vs Delayed Retainer Delivery Using 3D Digital Model Analysis N/A
Enrolling by invitation NCT05591703 - Clinical Outcomes Following Transcutaneous Auricular Neurostimulation to Improve Relapse Prevention: A Long-term Follow-up Study
Active, not recruiting NCT00299923 - Study for Patients With Chronic HCV (GT 1 or 3) Who Relapsed to Previous (Peg)Interferon/ Ribavirin Combination Therapy Phase 3
Recruiting NCT04162041 - Topotecan Plus M6620 (VX-970) vs. Topotecan Alone in People With Relapsed Small-Cell Lung Cancer Phase 2
Recruiting NCT04228315 - Biomarkers of P. Vivax Relapse N/A